Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats

Kohtaro Abe, Michie Toba, Abdallah Alzoubi, Karel Koubsky, Masako Ito, Hiroki Ota, Salina Gairhe, William T. Gerthoffer, Karen A. Fagan, Ivan F. McMurtry, Masahiko Oka

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Tyrosine kinase inhibitors are promising for the treatment of severe pulmonary hypertension. Their therapeutic effects are postulated to be due to inhibition of cell growth-related kinases and attenuation of vascular remodeling. Their potential vasodilatory activities have not been explored. Vasorelaxant effects of the tyrosine kinase inhibitors imatinib, sorafenib, and nilotinib were examined in isolated pulmonary arterial rings from normal and pulmonary hypertensive rats. Phosphorylation of myosin light chain phosphatase and myosin light chain was assessed by Western blots. Acute hemodynamic effects of imatinib were tested in the pulmonary hypertensive rats. In normal pulmonary arteries, imatinib reversed serotoninand U46619-induced contractions in a concentration-dependent and endothelium-independent manner. Sorafenib and nilotinib relaxed U46619-induced contraction. Imatinib inhibited activation of myosin phosphatase induced by U46619 in normal pulmonary arteries. All three tyrosine kinase inhibitors concentration-dependently and completely reversed the spontaneous contraction of hypertensive pulmonary arterial rings unmasked by inhibition of nitric oxide synthase. Acute intravenous administration of imatinib reduced high right ventricular systolic pressure in pulmonary hypertensive rats, with little effect on left ventricular systolic pressure and cardiac output. We conclude that tyrosine kinase inhibitors have potent pulmonary vasodilatory activity, which could contribute to their long-term beneficial effect against pulmonary hypertension. Vascular smooth muscle relaxation mediated via activation of myosin light chain phosphatase (Ca 2+ desensitization) appears to play a role in the imatinib-induced pulmonary vasodilation.

Original languageEnglish
Pages (from-to)804-808
Number of pages5
JournalAmerican journal of respiratory cell and molecular biology
Volume45
Issue number4
DOIs
Publication statusPublished - Oct 1 2011
Externally publishedYes

Fingerprint

Vasodilator Agents
Protein-Tyrosine Kinases
Rats
Myosin-Light-Chain Phosphatase
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Lung
Ventricular Pressure
Pulmonary Hypertension
Pulmonary Artery
Chemical activation
Myosin Light Chains
Phosphorylation
Blood Pressure
Hemodynamics
Cell growth
Muscle Relaxation
Nitric Oxide Synthase
Therapeutic Uses
Muscle
Imatinib Mesylate

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Clinical Biochemistry
  • Cell Biology

Cite this

Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. / Abe, Kohtaro; Toba, Michie; Alzoubi, Abdallah; Koubsky, Karel; Ito, Masako; Ota, Hiroki; Gairhe, Salina; Gerthoffer, William T.; Fagan, Karen A.; McMurtry, Ivan F.; Oka, Masahiko.

In: American journal of respiratory cell and molecular biology, Vol. 45, No. 4, 01.10.2011, p. 804-808.

Research output: Contribution to journalArticle

Abe, K, Toba, M, Alzoubi, A, Koubsky, K, Ito, M, Ota, H, Gairhe, S, Gerthoffer, WT, Fagan, KA, McMurtry, IF & Oka, M 2011, 'Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats', American journal of respiratory cell and molecular biology, vol. 45, no. 4, pp. 804-808. https://doi.org/10.1165/rcmb.2010-0371OC
Abe, Kohtaro ; Toba, Michie ; Alzoubi, Abdallah ; Koubsky, Karel ; Ito, Masako ; Ota, Hiroki ; Gairhe, Salina ; Gerthoffer, William T. ; Fagan, Karen A. ; McMurtry, Ivan F. ; Oka, Masahiko. / Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. In: American journal of respiratory cell and molecular biology. 2011 ; Vol. 45, No. 4. pp. 804-808.
@article{297a615e84d44011b34ffaf3c33001b0,
title = "Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats",
abstract = "Tyrosine kinase inhibitors are promising for the treatment of severe pulmonary hypertension. Their therapeutic effects are postulated to be due to inhibition of cell growth-related kinases and attenuation of vascular remodeling. Their potential vasodilatory activities have not been explored. Vasorelaxant effects of the tyrosine kinase inhibitors imatinib, sorafenib, and nilotinib were examined in isolated pulmonary arterial rings from normal and pulmonary hypertensive rats. Phosphorylation of myosin light chain phosphatase and myosin light chain was assessed by Western blots. Acute hemodynamic effects of imatinib were tested in the pulmonary hypertensive rats. In normal pulmonary arteries, imatinib reversed serotoninand U46619-induced contractions in a concentration-dependent and endothelium-independent manner. Sorafenib and nilotinib relaxed U46619-induced contraction. Imatinib inhibited activation of myosin phosphatase induced by U46619 in normal pulmonary arteries. All three tyrosine kinase inhibitors concentration-dependently and completely reversed the spontaneous contraction of hypertensive pulmonary arterial rings unmasked by inhibition of nitric oxide synthase. Acute intravenous administration of imatinib reduced high right ventricular systolic pressure in pulmonary hypertensive rats, with little effect on left ventricular systolic pressure and cardiac output. We conclude that tyrosine kinase inhibitors have potent pulmonary vasodilatory activity, which could contribute to their long-term beneficial effect against pulmonary hypertension. Vascular smooth muscle relaxation mediated via activation of myosin light chain phosphatase (Ca 2+ desensitization) appears to play a role in the imatinib-induced pulmonary vasodilation.",
author = "Kohtaro Abe and Michie Toba and Abdallah Alzoubi and Karel Koubsky and Masako Ito and Hiroki Ota and Salina Gairhe and Gerthoffer, {William T.} and Fagan, {Karen A.} and McMurtry, {Ivan F.} and Masahiko Oka",
year = "2011",
month = "10",
day = "1",
doi = "10.1165/rcmb.2010-0371OC",
language = "English",
volume = "45",
pages = "804--808",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "4",

}

TY - JOUR

T1 - Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats

AU - Abe, Kohtaro

AU - Toba, Michie

AU - Alzoubi, Abdallah

AU - Koubsky, Karel

AU - Ito, Masako

AU - Ota, Hiroki

AU - Gairhe, Salina

AU - Gerthoffer, William T.

AU - Fagan, Karen A.

AU - McMurtry, Ivan F.

AU - Oka, Masahiko

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Tyrosine kinase inhibitors are promising for the treatment of severe pulmonary hypertension. Their therapeutic effects are postulated to be due to inhibition of cell growth-related kinases and attenuation of vascular remodeling. Their potential vasodilatory activities have not been explored. Vasorelaxant effects of the tyrosine kinase inhibitors imatinib, sorafenib, and nilotinib were examined in isolated pulmonary arterial rings from normal and pulmonary hypertensive rats. Phosphorylation of myosin light chain phosphatase and myosin light chain was assessed by Western blots. Acute hemodynamic effects of imatinib were tested in the pulmonary hypertensive rats. In normal pulmonary arteries, imatinib reversed serotoninand U46619-induced contractions in a concentration-dependent and endothelium-independent manner. Sorafenib and nilotinib relaxed U46619-induced contraction. Imatinib inhibited activation of myosin phosphatase induced by U46619 in normal pulmonary arteries. All three tyrosine kinase inhibitors concentration-dependently and completely reversed the spontaneous contraction of hypertensive pulmonary arterial rings unmasked by inhibition of nitric oxide synthase. Acute intravenous administration of imatinib reduced high right ventricular systolic pressure in pulmonary hypertensive rats, with little effect on left ventricular systolic pressure and cardiac output. We conclude that tyrosine kinase inhibitors have potent pulmonary vasodilatory activity, which could contribute to their long-term beneficial effect against pulmonary hypertension. Vascular smooth muscle relaxation mediated via activation of myosin light chain phosphatase (Ca 2+ desensitization) appears to play a role in the imatinib-induced pulmonary vasodilation.

AB - Tyrosine kinase inhibitors are promising for the treatment of severe pulmonary hypertension. Their therapeutic effects are postulated to be due to inhibition of cell growth-related kinases and attenuation of vascular remodeling. Their potential vasodilatory activities have not been explored. Vasorelaxant effects of the tyrosine kinase inhibitors imatinib, sorafenib, and nilotinib were examined in isolated pulmonary arterial rings from normal and pulmonary hypertensive rats. Phosphorylation of myosin light chain phosphatase and myosin light chain was assessed by Western blots. Acute hemodynamic effects of imatinib were tested in the pulmonary hypertensive rats. In normal pulmonary arteries, imatinib reversed serotoninand U46619-induced contractions in a concentration-dependent and endothelium-independent manner. Sorafenib and nilotinib relaxed U46619-induced contraction. Imatinib inhibited activation of myosin phosphatase induced by U46619 in normal pulmonary arteries. All three tyrosine kinase inhibitors concentration-dependently and completely reversed the spontaneous contraction of hypertensive pulmonary arterial rings unmasked by inhibition of nitric oxide synthase. Acute intravenous administration of imatinib reduced high right ventricular systolic pressure in pulmonary hypertensive rats, with little effect on left ventricular systolic pressure and cardiac output. We conclude that tyrosine kinase inhibitors have potent pulmonary vasodilatory activity, which could contribute to their long-term beneficial effect against pulmonary hypertension. Vascular smooth muscle relaxation mediated via activation of myosin light chain phosphatase (Ca 2+ desensitization) appears to play a role in the imatinib-induced pulmonary vasodilation.

UR - http://www.scopus.com/inward/record.url?scp=80052092055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052092055&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2010-0371OC

DO - 10.1165/rcmb.2010-0371OC

M3 - Article

C2 - 21378262

AN - SCOPUS:80052092055

VL - 45

SP - 804

EP - 808

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 4

ER -